Michelino De Laurentiis
Advertisement
Articles by Michelino De Laurentiis
TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study
ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri,Seock-Ah Im,Senia Pernas,Michelino De Laurentiis,Shusen Wang,Noelia Martínez Jañez,Giuliano Borges,David W. Cescon,Masaya Hattori,Yen-Shen Lu,Erika P. Hamilton, MD,Qingyuan Zhang,Junji Tsurutani,Kevin Kalinsky, MD, MS,Lu Xu,Neelima Denduluri,Binghe Xu,Barbara Pistilli
Advertisement
Latest Updated Articles
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEEPublished: June 24th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How to Address Racial and Social Disparities in Pancreatic Cancer Care?
2
Handling the Burden of Financial Toxicity While Undergoing Cancer Therapy
3
HR 2541: How May Its Implementation Impact Radiation Oncology Practice?
4
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
5
